WINTON GROUP Ltd bought a new stake in shares of Indivior PLC (NASDAQ:INDV – Free Report) during the second quarter, Holdings Channel reports. The fund bought 22,143 shares of the company’s stock, valued at approximately $909,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its holdings in Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after acquiring an additional 1,299,425 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Indivior by 2,597.9% during the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock worth $9,327,000 after purchasing an additional 958,132 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Indivior by 669.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 391,386 shares of the company’s stock worth $5,769,000 after purchasing an additional 340,498 shares during the last quarter. Prudential Financial Inc. acquired a new position in shares of Indivior during the 2nd quarter worth about $207,000. Finally, Walleye Capital LLC purchased a new position in Indivior in the 2nd quarter valued at about $594,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.
Wall Street Analyst Weigh In
INDV has been the topic of several research analyst reports. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a report on Monday, June 29th. Craig Hallum reissued a “buy” rating and set a $53.00 target price on shares of Indivior in a report on Tuesday, August 4th. Weiss Ratings upgraded Indivior from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, September 4th. Finally, Barclays lowered their price target on Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 5th. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $45.17.
Indivior Price Performance
Shares of NASDAQ INDV opened at $34.49 on Monday. The firm has a 50-day simple moving average of $38.18 and a 200-day simple moving average of $36.06. The stock has a market capitalization of $4.07 billion, a price-to-earnings ratio of 12.36 and a beta of 0.82. Indivior PLC has a 52 week low of $22.22 and a 52 week high of $42.81.
Indivior (NASDAQ:INDV – Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share for the quarter. The firm had revenue of $343.00 million for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. As a group, equities research analysts expect that Indivior PLC will post 3.66 EPS for the current year.
Insider Transactions at Indivior
In other Indivior news, insider Christian Heidbreder sold 18,586 shares of the stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $41.14, for a total value of $764,628.04. Following the completion of the sale, the insider owned 209,337 shares in the company, valued at approximately $8,612,124.18. This represents a 8.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Woodrow D. Anderson bought 1,500 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was acquired at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the completion of the purchase, the chief accounting officer directly owned 27,638 shares in the company, valued at approximately $986,400.22. This represents a 5.74% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.74% of the stock is currently owned by corporate insiders.
About Indivior
Indivior plc is a specialty pharmaceutical company focused on developing and commercializing medicines for addiction and serious mental health disorders. Its portfolio is primarily centered on treatments for opioid use disorder, with an emphasis on products designed to support recovery, reduce illicit opioid use and address the risk of overdose.
The company’s key products include SUBOXONE sublingual film, a buprenorphine-and-naloxone treatment for opioid use disorder; SUBLOCADE, a long-acting injectable form of buprenorphine; and OPVEE, a nalmefene nasal spray intended for the emergency treatment of opioid overdose.
Recommended Stories
- Five stocks we like better than Indivior
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDV – Free Report).
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
